Abstract
Effectively targeting deregulated KRAS signaling remains an unmet clinical need, as current approaches commonly lead to the development of chemoresistance in clinical settings. ADAM9-mediated lysosomal KRAS degradation is now shown to counteract PDAC chemoresistance independently of mutational status.
| Original language | English |
|---|---|
| Pages (from-to) | 375-377 |
| Number of pages | 3 |
| Journal | Nature Cancer |
| Volume | 5 |
| Issue number | 3 |
| DOIs |
|
| State | Published - Mar 2024 |
